cis,cis-3.4-Dimethylcyclopentanol | 26704-30-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: cis,cis-3.4-Dimethylcyclopentanol
• 英文别名: cis-3,4-Dimethylcyclopentanol
• CAS: 26704-30-3
• 化学式: C₇H₁₄O
• 分子量: 114.188
• InChiKey: UMJCOSIPVBOCGS-ZMONIFLSSA-N

物化性质

• 沸点：
  159.2±8.0 °C(Predicted)
• 密度：
  0.908±0.06 g/cm3(Predicted)

文献信息

• METHODS FOR TREATING HCV
  申请人：Delaney William E.

  公开号：US20130273005A1

  公开（公告）日：2013-10-17

  This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

  这项发明涉及治疗丙型肝炎病毒感染的治疗分子组合。本发明涉及方法、用途、给药方案和组合物。
• CDK2/4/6 Inhibitors
  申请人：Pfizer Inc.

  公开号：US20180044344A1

  公开（公告）日：2018-02-15

  This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R 1 , R 2 , R 2A , R 2B , R 3 , R 4 , R 5A , R 5B , R 6 , R 7 , R 8 , R 9 , p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

  这项发明涉及一般式（I）的化合物及其药用盐，其中R1、R2、R2A、R2B、R3、R4、R5A、R5B、R6、R7、R8、R9、p、q和r如本文所定义，以及包含这些化合物和盐的药物组合物，以及使用这些化合物、盐和组合物治疗异常细胞增长，包括癌症的方法。
• OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE
  申请人：XUANZHU PHARMA CO., LTD.

  公开号：US20150191502A1

  公开（公告）日：2015-07-09

  The present invention belongs to the field of pharmaceutical technology, more specifically relates to optically pure benzyl-4-chlorophenyl-C-glucoside derivatives represented by formulae (II) and (III), a process for preparing these compounds and intermediates thereof, a pharmaceutical formulation and a pharmaceutical composition containing these compounds, and the use of the optically pure benzyl-4-chlorophenyl-C-glucoside derivative as a sodium glucose co-transporter (SGLT) inhibitor in manufacture of a medicament for treating and/or preventing diabetes mellitus (including insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus) or diabetes-associated diseases (including insulin resistance disease and obesity)

  该发明属于制药技术领域，更具体地涉及由化学式（II）和（III）代表的光学纯苄基-4-氯苯基-C-葡萄糖苷衍生物，以及制备这些化合物及其中间体的方法，包含这些化合物的制药配方和制药组合物，以及将光学纯苄基-4-氯苯基-C-葡萄糖苷衍生物用作钠葡萄糖共转运蛋白（SGLT）抑制剂，用于制造治疗和/或预防糖尿病（包括胰岛素依赖型糖尿病和非胰岛素依赖型糖尿病）或与糖尿病相关疾病（包括胰岛素抵抗症和肥胖症）的药物。
• ANTIVIRAL COMPOUNDS
  申请人：Cottell Jeromy J.

  公开号：US20140051626A1

  公开（公告）日：2014-02-20

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  该发明涉及抗病毒化合物、含有这种化合物的组合物、包括给予这种化合物的治疗方法，以及用于制备这种化合物的过程和中间体。
• BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS
  申请人：Thomas Jermaine

  公开号：US20140309190A1

  公开（公告）日：2014-10-16

  Compounds that have agonist activity at one or more of the S 1 P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S 1 P receptors.

  提供具有一种或多种S1P受体激动剂活性的化合物。这些化合物是鞘氨醇类似物，在磷酸化后，可以在S1P受体上表现为激动剂。